.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Farmers Insurance
Baxter
UBS
Federal Trade Commission
Express Scripts
US Army
Covington
Harvard Business School
Julphar

Generated: December 18, 2017

DrugPatentWatch Database Preview

Halobetasol propionate - Generic Drug Details

« Back to Dashboard

What are the generic sources for halobetasol propionate and what is the scope of halobetasol propionate patent protection?

Halobetasol propionate
is the generic ingredient in two branded drugs marketed by Fougera Pharms, G And W Labs, Perrigo Israel, Taro, Sun Pharm Inds Ltd, Sun Pharm Industries, G And W Labs Inc, and Ranbaxy, and is included in twelve NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Halobetasol propionate has fourteen patent family members in fourteen countries.

There are nine drug master file entries for halobetasol propionate. Nine suppliers are listed for this compound.

Summary for halobetasol propionate

Pharmacology for halobetasol propionate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
G And W Labs IncHALOBETASOL PROPIONATEhalobetasol propionateOINTMENT;TOPICAL077109-001Jun 14, 2005DISCNNoNo► Subscribe► Subscribe► Subscribe
Perrigo IsraelHALOBETASOL PROPIONATEhalobetasol propionateCREAM;TOPICAL077123-001Dec 16, 2004ABRXNoNo► Subscribe► Subscribe► Subscribe
TaroHALOBETASOL PROPIONATEhalobetasol propionateCREAM;TOPICAL077227-001Aug 4, 2005ABRXNoNo► Subscribe► Subscribe► Subscribe
Perrigo IsraelHALOBETASOL PROPIONATEhalobetasol propionateOINTMENT;TOPICAL076872-001Dec 16, 2004ABRXNoNo► Subscribe► Subscribe► Subscribe
TaroHALOBETASOL PROPIONATEhalobetasol propionateOINTMENT;TOPICAL076994-001Dec 16, 2004ABRXNoNo► Subscribe► Subscribe► Subscribe
G And W LabsHALOBETASOL PROPIONATEhalobetasol propionateOINTMENT;TOPICAL077721-001Sep 7, 2006ABRXNoYes► Subscribe► Subscribe► Subscribe
Sun Pharm IndustriesULTRAVATEhalobetasol propionateLOTION;TOPICAL208183-001Nov 6, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
G And W LabsHALOBETASOL PROPIONATEhalobetasol propionateCREAM;TOPICAL078162-001Apr 24, 2007ABRXNoYes► Subscribe► Subscribe► Subscribe
Sun Pharm IndustriesULTRAVATEhalobetasol propionateLOTION;TOPICAL208183-001Nov 6, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Sun Pharm Inds LtdULTRAVATEhalobetasol propionateCREAM;TOPICAL019967-001Dec 27, 1990ABRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: halobetasol propionate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sun Pharm Inds LtdULTRAVATEhalobetasol propionateCREAM;TOPICAL019967-001Dec 27, 1990► Subscribe► Subscribe
RanbaxyULTRAVATEhalobetasol propionateOINTMENT;TOPICAL019968-001Dec 17, 1990► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: halobetasol propionate

Country Document Number Estimated Expiration
Mexico2015004863► Subscribe
China104884043► Subscribe
Eurasian Patent Organization201590730► Subscribe
World Intellectual Property Organization (WIPO)2014062817► Subscribe
Philippines12015500859► Subscribe
South Korea20150069005► Subscribe
Hong Kong1214154► Subscribe
Canada2888853► Subscribe
India4160DEN2015► Subscribe
European Patent Office2919753► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Deloitte
Teva
Argus Health
Medtronic
Cipla
Dow
AstraZeneca
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot